Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort-Reference-Cited by-同舟云学术

Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort

Published:2016-09-06 Issue:2 Volume:54 Page:691-705
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Klafki Hans-W.¹,Hafermann Henning²,Bauer Chris³,Haussmann Ute²,Kraus Inga¹⁴,Schuchhardt Johannes³,Muck Stephan⁵,Scherbaum Norbert²,Wiltfang Jens¹⁴

Affiliation:

1. Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Georg-August-University, Goettingen, Germany

2. LVR-Klinikum Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany

3. MicroDiscovery GmbH, Berlin, Germany

4. German Center for Neurodegenerative Diseases (DZNE), Research Site Goettingen, Germany

5. Memory Clinic at the Elisabeth Hospital, Geriatrie-Zentrum Haus Berge, Essen, Germany

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference21 articles.

1. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Sperling;Alzheimers Dement,2011

2. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert;Alzheimers Dement,2011

3. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;McKhann;Alzheimers Dement,2011

4. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria;Dubois;Lancet Neurol,2007

5. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Jack;Alzheimers Dement,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer’s disease with standardization of measurements?;Clinical Biochemistry;2023-02

2. Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?;Fluids and Barriers of the CNS;2022-12-03

3. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease;Alzheimer's Research & Therapy;2021-05-04

4. Alzheimer-Demenz: Neurobiologie, Diagnostik und experimentelle Ansätze;Geriatrie up2date;2020-10

5. Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits;Clinica Chimica Acta;2019-05